Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 5:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 2,130 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Colorectal cancer Clear all
Active, not recruiting Phase 2 Interventional

TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

NCT05343013
View directory record Official record
Conditions
Colorectal Cancer
Interventions
TAS-102
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 16, 2026, 5:23 PM EDT
Completed Not applicable Interventional

Oxaliplatin in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer

NCT00040820
View directory record Official record
Conditions
Colorectal Cancer
Interventions
oxaliplatin
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 16, 2026, 5:23 PM EDT
Terminated Phase 2 Interventional Results available

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

NCT04515394
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Tepotinib, Cetuximab
Drug · Biological
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Phoenix, Arizona • La Jolla, California • Santa Monica, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 16, 2026, 5:23 PM EDT
Completed Phase 1 Interventional

A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer

NCT02860780
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Colorectal Cancer, Non-small Cell Lung Cancer
Interventions
prexasertib, ralimetinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Charlotte, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 14, 2018 · Synced Oct 16, 2026, 5:23 PM EDT
Completed Phase 1 Interventional

Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer

NCT00004879
View directory record Official record
Conditions
Colorectal Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer, Prostate Cancer
Interventions
panitumumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Los Angeles, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Oct 16, 2026, 5:23 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Microbiome in Colorectal Cancer Onset and Progression

NCT05368688
View directory record Official record
Conditions
Colorectal Cancer, Tumor, CRC, GI Cancer, Gastrointestinal Cancer
Interventions
Not listed
Lead sponsor
Viome
Industry
Eligibility
50 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Oct 16, 2026, 5:23 PM EDT
Completed Phase 4 Interventional

Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia

NCT01471756
View directory record Official record
Conditions
Neoplasms, Gastric Cancer
Interventions
Standard of Care Procedure as described in ARM
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 16, 2026, 5:23 PM EDT
Recruiting Not applicable Interventional

Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy

NCT07234968
View directory record Official record
Conditions
Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma, Pelvic Malignancy, Bladder Transitional Cell Carcinoma, Bladder Neoplasm
Interventions
Ureteral Stent Placement, No Ureteral Stent, Indocyanine Green with Fluorescence Imaging
Procedure · Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 16, 2026, 5:23 PM EDT
Terminated Phase 1 Interventional

Regorafenib + Panitumumab for Colorectal Cancers

NCT02199223
View directory record Official record
Conditions
KRAS and NRAS Wild-type Colorectal Cancer
Interventions
regorafenib + panitumumab
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 16, 2026, 5:23 PM EDT
Recruiting Not applicable Interventional

Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

NCT04751435
View directory record Official record
Conditions
Educational Materials for Genetic Testing, Breast Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Colorectal Cancer
Interventions
Cognitive interview, LCAM intervention, Standard of care
Other · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Brooklyn, New York • Jamaica, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 16, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Results available

Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer

NCT01154335
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
OSI-906, Everolimus
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Fort Myers, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 16, 2026, 5:23 PM EDT
Terminated Not applicable Interventional Results available

Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma

NCT04276090
View directory record Official record
Conditions
Bile Duct Neoplasms, Colorectal Neoplasms
Interventions
Hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter., Hepatic artery infusion pump floxuridine and dexamethasone, Systemic chemotherapy for colorectal liver metastases, Systemic chemotherapy for intrahepatic cholangiocarcinoma
Device · Drug
Lead sponsor
Michael J Cavnar, MD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 16, 2026, 5:23 PM EDT
Completed Phase 3 Interventional

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer

NCT00056446
View directory record Official record
Conditions
Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
Interventions
Vatalanib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
143
States / cities
Huntsville, Alabama • Anchorage, Alaska • Tucson, Arizona + 113 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 16, 2026, 5:23 PM EDT
Completed Phase 1 Interventional

VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer

NCT03373188
View directory record Official record
Conditions
Colon Carcinoma Metastatic in the Liver, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
Interventions
Anti-SEMA4D Monoclonal Antibody VX15/2503, Ipilimumab, Nivolumab, Surgery
Biological · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Atlanta, Georgia • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 16, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Results available

Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors

NCT00195260
View directory record Official record
Conditions
Neoplasms
Interventions
bosutinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
19
States / cities
Birmington, Alabama • Scottsdale, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 16, 2026, 5:23 PM EDT
Completed Phase 1 Interventional

Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma

NCT02248805
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
MGD007
Drug
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
New Haven, Connecticut • Tampa, Florida • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 16, 2026, 5:23 PM EDT
Completed Phase 1 Interventional

Interleukin-12 in Treating Patients With Cancer in the Abdomen

NCT00003046
View directory record Official record
Conditions
Anal Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer
Interventions
Recombinant Interleukin-12
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 16, 2026, 5:23 PM EDT
Terminated Phase 1 Interventional

Study of ASN003 in Subjects With Advanced Solid Tumors

NCT02961283
View directory record Official record
Conditions
Neoplasms, Melanoma, Colorectal Neoplasm, Carcinoma, Non-small Cell Lung
Interventions
ASN003 ascending doses, ASN003 MTD
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 16, 2026, 5:23 PM EDT
Completed Phase 2 Interventional

Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer

NCT00123851
View directory record Official record
Conditions
Colorectal Cancer, Neoplasm Metastasis
Interventions
Tarceva (OSI-774), Capecitabine, Oxaliplatin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2009 · Synced Oct 16, 2026, 5:23 PM EDT
Completed Phase 2 Interventional

Bevacizumab Plus Fluorouracil and Leucovorin in Treating Patients With Locally Advanced or Metastatic Stage IV Colorectal Cancer That Has Progressed After Standard Chemotherapy

NCT00066846
View directory record Official record
Conditions
Colorectal Cancer
Interventions
bevacizumab, fluorouracil, leucovorin calcium
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
33
States / cities
Anchorage, Alaska • Los Angeles, California • Aurora, Colorado + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 16, 2026, 5:23 PM EDT
Terminated Phase 3 Interventional Results available

Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy

NCT00499369
View directory record Official record
Conditions
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
irinotecan hydrochloride, leucovorin calcium, fluorouracil, cetuximab, bevacizumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
382
States / cities
Fort Smith, Arkansas • Burbank, California • Castro Valley, California + 259 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Oct 16, 2026, 5:23 PM EDT
Withdrawn No phase listed Observational

A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation After Clinical Complete Response to Neoadjuvant Therapy for Rectal Cancer

NCT03749083
View directory record Official record
Conditions
Gastrointestinal Malignancies
Interventions
The Functional Assessment of Cancer Therapy- Colorectal
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Timeline
2019 – 2024
U.S. locations
4
States / cities
Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Oct 16, 2026, 5:23 PM EDT
Completed Phase 2 Interventional

A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer

NCT00048126
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Irinotecan, capecitabine [Xeloda]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
10
States / cities
Hoover, Alabama • La Jolla, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 16, 2026, 5:23 PM EDT
Completed Phase 1 Interventional

Curcumin Biomarkers

NCT01333917
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Curcumin C3 tablet
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 16, 2026, 5:23 PM EDT